Expertise in
14
conditions

Dr. David F. Lee

Radiation Oncology
Marshfield Medical Center-Minocqua Medical Offices-Cancer Care
9576 Highway 70, 
Minocqua, WI 
Accepting New Patients
Offers Telehealth
18 Years of Experience
Expertise in
14
conditions
Marshfield Medical Center-Minocqua Medical Offices-Cancer Care
9576 Highway 70, 
Minocqua, WI 

Overview

David Lee is a Radiation Oncologist practicing medicine in Minocqua, Wisconsin. He has been practicing medicine for over 18 years.

Dr. Lee is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC).

He is actively involved in clinical research, participating in 6 clinical trials. Dr. Lee is currently accepting new patients.

Graduate Year

2008

Specialties

Radiation Oncology

Licenses

Radiology in WI

Hospital Affiliations

Marshfield Medical Center - Weston
Aspirus Rhinelander Hospital
Flambeau Hospital
Marshfield Medical Center
Marshfield Medical Center - Minocqua

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Marshfield Medical Center-Minocqua Medical Offices-Cancer Care
9576 Highway 70, Minocqua, WI 54548

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Expertise in
2
conditions
Dr. Hari J. Menon
Radiation Oncology
Expertise in
2
conditions
Dr. Hari J. Menon
Radiation Oncology
Referral may be required

Langlade Hospital Hotel Dieu St Joseph O

501 Aurora St, 
Antigo, WI 
 (58.7 miles away)
Languages Spoken:
English
See accepted insurances

Hari Menon is a Radiation Oncologist practicing medicine in Antigo, Wisconsin. Dr. Menon is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Primary Mediastinal B-Cell Lymphoma (PMBCL), and Penectomy.

Frequently Asked Questions about Dr. David F. Lee

How do I make an appointment with Dr. David F. Lee?

You can book an appointment with Dr. David F. Lee by calling their office at 715-358-1861. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David F. Lee a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David F. Lee is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David F. Lee specialize in?

While Dr. David F. Lee is a Radiation Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. David F. Lee accept my insurance?

Dr. David F. Lee accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 715-358-1861 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 57 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile